Effects of molecular targeting agents and immune-checkpoint inhibitors in patients with advanced cancer who are near the end of life.

Age, ECOG-PS, primary cancer site, the number of comorbidities, MTAs, and ICIs use were significant associated with SACT near EOL. Information on these factors may aid clinical decision making in referral to palliative care institutes.